Comparative Pharmacology
Head-to-head clinical analysis: BACLOFEN versus RYANODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACLOFEN versus RYANODEX.
BACLOFEN vs RYANODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
Ryanodine receptor agonist; stabilizes the ryanodine receptor (RyR1) channel in skeletal muscle, reducing calcium leakage and improving excitation-contraction coupling.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
Dantrolene sodium: 2.5 mg/kg IV bolus, repeated as needed up to a cumulative dose of 10 mg/kg, then 1 mg/kg IV every 6 hours for 24-48 hours following malignant hyperthermia crisis.
None Documented
None Documented
Clinical Note
moderateBaclofen + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Baclofen is combined with Fluticasone propionate."
Clinical Note
moderateBaclofen + Clemastine
"The risk or severity of adverse effects can be increased when Baclofen is combined with Clemastine."
Clinical Note
moderateBaclofen + Venlafaxine
"The risk or severity of adverse effects can be increased when Baclofen is combined with Venlafaxine."
Clinical Note
moderateBaclofen + Nefazodone
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Terminal elimination half-life is approximately 1.5-2 hours in healthy adults; prolonged in patients with hepatic impairment.
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for the majority of elimination.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The risk or severity of adverse effects can be increased when Baclofen is combined with Nefazodone."